ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

Letters: Kopans To Broder: Response Ignores Major Questions

October 15, 1993

DCPC Concepts Approved For Tw Grants Support Contract

January 31, 1986

Senate Subcommittee Seeking $2 Billion In for NIH, Bumps Up Against Caps

June 25, 1999

OSU Continues As comprehensive Center; City Of Hope BMT Program Wins 5-Year Grant.

July 14, 2000

In Brief: Pitot Appointed To Cancer Panel, Replacing Jako; Fisher, Wattenberg, Curtiss Lead Cancer Groups

May 29, 1992